United States

Orion Oyj (ORNBV.HE)

ORNBV.HE on Helsinki Stock Exchange

24 Mar 2017
Change (% chg)

€-0.27 (-0.55%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Orion Oyj Q4 EBIT at EUR 58.7 million, above estimates
Wednesday, 8 Feb 2017 05:01am EST 

Orion Oyj : Q4 sales 279.9 million euros ($298.18 million) versus 273 million euros seen in Reuters poll . Q4 EBIT 58.7 million euros (Reuters poll 56.5 million) . Proposes dividend of 1.35 euro per share and 0.20 euro special dividend per share, in total 1.55 euro per share (Reuters poll: 1.45 euro per share) . Says net sales of business division turned to growth in 2016 for first time since start of generic competition for Parkinson's franchise . CEO says "Clear growth in operating profit is explained by growth in net sales and about 22 million euros of total capital gains" .Sees 2017 net sales at similar level to 2016 and operating profit ex. material capital gains to be at least 280 million euros.  Full Article

Orion to divest food business into new subsidiary for system transformation
Tuesday, 22 Nov 2016 04:42am EST 

Orion Corp <001800.KS> : Says it will divest its food business into a new subsidiary, named Orion Corp . Says it will change company name to Orion Holdings Corp and will be engaged in subsidiary management and investment, for holding company system transformation .Divesture effective date is June 1, 2017 and expected registered date is June 5, 2017.  Full Article

Orion Oyj and Menarini Group enter into collaboration agreement
Friday, 2 Sep 2016 06:10am EDT 

Orion Oyj : Says the company and Menarini Group collaborate on budesonide-formoterol Easyhaler combination product for asthma and COPD . Agreement is for co-marketing of Easyhaler in Germany, Italy, Spain, and Portugal . Parties have also agreed on exclusive license and distribution arrangement in France and Turkey . Parties will market budesonide-formoterol Easyhaler under their own brands .Menarini Group is Italian pharmaceutical company.  Full Article

Orion Q2 EBIT beats expectations at EUR 83.5 million
Tuesday, 19 Jul 2016 05:00am EDT 

Orion Oyj : Q2 EBIT 83.5 million euros ($92.4 million) (Reuters poll 74.4 million euros) . Q2 sales 273.1 million euros (Reuters poll 266 million euros) . Estimates that in 2016 net sales will be slightly higher than in 2015 .2016 operating profit excluding possible capital gains is estimated to exceed 270 million euros.  Full Article

Orion Corporation and Asahi Kasei enters into global strategic collaboration
Wednesday, 22 Jun 2016 01:00am EDT 

Orion Oyj : Says that it has entered into a global strategi collaboration agreement with Japanese Asahi Kasei Pharma for the discovery, development and commercialisation of assets in pain management . Agreement comprises a total of four discovery phase candidates, two from Asahi Kasei and two from Orion .Collaboration allows both companies to exclusively license others' development-ready programs at pre-determined stages.  Full Article

Orion completes share buyback
Thursday, 16 Jun 2016 03:37am EDT 

Orion Oyj : Said on Wednesday it completed share acquisitions . Bought total of 500,000 own B shares at average price of about 33.5319 euros per share . Total purchase price was 16,765,946.50 euros ($18.89 million) .It holds now total of 783,366 own B shares corresponding to about 0.55 pct of total number of shares and 0.09 pct of votes.  Full Article

Orion upgrades full-year outlook for 2016
Wednesday, 15 Jun 2016 03:20am EDT 

Orion Oyj : Orion upgrades full-year outlook for 2016 . Net sales are estimated to be slightly higher than in 2015 . Now sees 2016 operating profit without potential capital gains is estimated to exceed 270 million euros (operating profit was 267 million euros in 2015 .Shares rise 4 percent.  Full Article

Orion and Bayer start new phase III study of prostate cancer drug
Friday, 3 Jun 2016 02:30am EDT 

Orion Oyj : Says Orion and Bayer expand clinical development program for ODM-201 and initiate a new phase III study Arasens in patients with metastatic hormone-sensitive prostate cancer . Says new the study will evaluate the safety and efficacy of the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel in men with newly diagnosed metastatic hormone-sensitive prostate cancer .Says new trial is expected to start the enrolment of patients towards the end of 2016.  Full Article

Finland's Orion to buy back shares
Wednesday, 27 Apr 2016 05:15am EDT 

Orion Oyj:Decision by the board of directors to acquire own shares.500,000 class B shares will be acquired, acquisition will be started at earliest on 4 May and it can continue until further notice.  Full Article

Orion gives guidance on FY 2016, proposes dividend for FY 2015
Tuesday, 2 Feb 2016 05:00am EST 

Orion Oyj:Proposes a dividend of 1.30 euros per share for FY 2015.For FY 2016 expects its operating profit to exceed 240 million euros, compared to 267 million euros it reported from FY 2015.  Full Article

More From Around the Web

BRIEF-Orion Oyj Q4 EBIT at EUR 58.7 million, above estimates

* Q4 sales 279.9 million euros ($298.18 million) versus 273 million euros seen in Reuters poll